One-Shot gene therapy aims to free patients from monthly eye injections
Disease control
Recruiting now
This large, late-stage trial is testing whether a single gene therapy injection into the eye (called LX102) can work as well as or better than the standard monthly eye injections for wet age-related macular degeneration. The main goal is to see if the one-time treatment can impro…
Phase: PHASE3 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC